Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) is set to participate in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pacira BioSciences, Inc. (NASDAQ: PCRX) is set to participate in the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 AM ET. The presentation will be virtual, and investors can access the pre-recorded audio via the company's website. Pacira is recognized for its leadership in non-opioid pain management, particularly through its long-acting local analgesic, EXPAREL®, which launched in April 2012. The company also acquired the iovera°® system in 2019 to enhance its offerings in regenerative health solutions.
Details
News Market Reaction – PCRX
The recorded move for PCRX in the trading session of this news was +0.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARSIPPANY, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference at 7:00 AM ET on Monday, September 13, 2021. Pre-recorded audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
About Pacira
Pacira BioSciences, Inc. (Nasdaq: PCRX) is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.